[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"constipation-chronic-idiopathic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:constipation-chronic-idiopathic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100547853","phase-2-maralixibat-in-patients-with-cystic-fibrosis-and-constipation-100547853",false,"NCT06413368","Maralixibat in Patients With Cystic Fibrosis and Constipation","Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study","Inclusion Criteria\n\n* Ages 1 to 18 years.\n* Proven diagnosis of Cystic Fibrosis confirmed by genetic testing or sweat chloride testing.\n* Proven diagnosis of chronic constipation, defined as a Bristol Stool Scale (BSS) score \\\u003C3 while on a stable conventional constipation therapy regimen.\n* Stable conventional constipation medication regimen (no medication changes or dose adjustments) for at least 4 weeks prior to enrollment. Conventional therapy may include stool softeners, stimulant laxatives, or dietary interventions.\n\nExclusion Criteria\n\n* Uncontrolled fat-soluble vitamin deficiency (Vitamin A, D, E, or K).\n* Changes to conventional constipation medication regimen within 4 weeks prior to initiation of Maralixibat.\n* Adequately treated chronic constipation, defined as a Bristol Stool Scale (BSS) score \\>3 on the current regimen.\n* Known allergy or sensitivity to Maralixibat or any study-related ingredients.\n* Inability or unwillingness of the participant or legal guardian\u002Frepresentative to provide written informed consent.","ALL","1 Year","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Chronic constipation is common in children with cystic fibrosis (CF), likely due to impaired chloride channel function that reduces intestinal secretions. Standard osmotic laxatives often provide inadequate relief in this population.\n\nMaralixibat is an ileal bile acid transporter inhibitor (IBATi) that increases the amount of bile acids reaching the colon. Bile acids can enhance intestinal secretion, reduce transit time, and soften stool. This study will evaluate whether Maralixibat improves stool consistency in children with CF who experience constipation.\n\nWe will enroll 20 children with CF and constipation, defined as a Bristol Stool Scale score \\\u003C4 for at least one week while on a stable laxative regimen. Each participant will receive Maralixibat for two weeks in addition to their usual laxatives. Families will record stool consistency and ease of defecation before and during treatment.\n\nThe primary objective is to determine whether Maralixibat improves stool consistency to a Bristol Stool Scale score \\>4. The secondary objective is to assess changes in ease of defecation using standardized questionnaires.",[28,29],"Constipation Chronic Idiopathic","Cystic Fibrosis",[31,29,32,33],"Maralixibiat","Chronic Constipation","Bristol Stool","RECRUITING","2026-04-16",{"date":37,"type":38},"2026-04-21","ACTUAL",{"date":40,"type":38},"2025-04-09",{"date":42,"type":21},"2027-06-30",{"name":44,"class":45},"Children's Hospital Los Angeles","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":74,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":46},"100622820","soluble-and-osmotic-fibre-solos-diet-for-constipation-100622820","NCT07388589","Soluble and Osmotic Fibre (SOLOS) Diet for Constipation","The Soluble and Osmotic Fibre (SOLOS) Diet for Functional Bowel Disorders With Constipation","SOLOS","Inclusion Criteria:\n\n* Presented with symptoms of FC, IBS-C, or SIBO-C\n* Were aged 18 to 70 years old. (Research focus is on adult patients, excluding older adults and children)\n* Date of baseline (first) and follow-up appointments ranged from January 2021 to December 2025\n* Did not attend follow-up appointments (Data would be treated as \"intention to treat\" and data points were carried forward for conservative analysis).\n\nExclusion Criteria:\n\n* Had no history of constipation-related symptoms (Does not relate to research question's population or outcome)\n* Started treatment before January 2021\n* Were not due for follow-up before the end of December 2025\n* Symptom and stool data inadequately recorded","70 Years",{"count":57,"type":21},180,"OBSERVATIONAL","This research aims to study the dual effectiveness of incorporating soluble fibre and osmotic carbohydrates (SOLOS), with or without restricting fructans and GOS, and present novel findings in managing GI symptoms in patients with functional bowel disorders with constipation. These findings may also support researchers and clinicians in shaping new dietary approaches in the management of general constipation symptoms.",[61,62,28,63,64,65,66,67,68,69,70,71,72,73],"Constipation","Constipation - Functional","Constipation Predominant Irritable Bowel Syndrome","Constipation, Signs and Symptoms, Digestive","Constipation-predominant IBS (IBS-C)","Constipation-predominant Irritable Bowel Syndrome","Constipation-predominant Irritable Bowel Syndrome (IBS-C)","Diet Therapy","Diet Modification","Diet, Food and Nutrition","Dietary and Nutritional Therapies","Dietary Fiber","Dietary Fibers",[61,75,76,77,78],"Functional constipation","Constipation-predominant irritable bowel syndrome (IBS-C)","Soluble fiber","osmotic sugar","NOT_YET_RECRUITING","2026-02-04",{"date":82,"type":38},"2026-02-06",{"date":84,"type":21},"2026-02-02",{"date":86,"type":21},"2027-03-01",{"name":88,"class":45},"Singapore Institute of Technology",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":46},"100580160","mowoot-and-trans-anal-irrigation-for-constipation-100580160","NCT06833684","MowOot and Trans-anal Irrigation fOr coNstipation","Intermittent Colonic Exoperistalsis Treatment With MOWOOT Medical Device to Treat Chronic Constipation in Adult Patients Waiting for Using Trans-Anal Irrigation: A Pilot Study","MOTION","Inclusion Criteria:\n\n1. Adult people (18 yo or older) of any gender\n2. Attending their pre-scheduled on-site visit to the site (The Sir Alan Parks Physiology \\& Pelvic Floor Biofeedback Unit \\| Central Middlesex Hospital) due to constipation (Symptoms meeting the American College of Gastroenterology definition of chronic constipation: unsatisfactory defaecation characterized by infrequent stool, difficult stool passage or both for at least previous 3 months.\n3. Bothered by their constipation\n4. Failed biofeedback (in absence of outlet problems)\n5. In waiting list to use TAI\n6. Able to undertake the treatment with the MOWOOT device or TAI themselves, or with a carer willing to do it\n7. Able to understand the study requirements\n8. Able to understand written and spoken English (due to questionnaire validity)\n9. Able and willing to provide written informed consent to participate\n\nExclusion Criteria:\n\nA subject will not be eligible for inclusion in this study if any of the following criteria apply:\n\nDisease phenotype exclusion criteria:\n\n* Irritable Bowel Syndrome with Diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBSmix): (not due to laxative use)\n* Inflammatory Bowel Disease (IBD)\n* Significant outlet problem\n* Trapping rectocele\n* Intra anal rectal intussusception\n* External rectal prolapse\n\nDevice-related exclusion criteria:\n\n* Abdominal perimeter ≤65cm or ≥130cm\n* Unable to independently use the MOWOOT technology, unless a carer is available daily to assist\n\nOther medical conditions, medications and contraindications:\n\n* Pregnancy or attempt to become pregnant in the next 6 months.\n* Previous large bowel resection\n* Active anorexia or bulimia\n* Active abdominal cancer\n* Large inguinal or umbilical hernia\n* Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal massage uncomfortable\n* Any condition that contraindicates abdominal massage.\n* Significant abdominal pain\n* Participation in another parallel interventional clinical trial or less than 2 months from participation in a previous interventional clinical trial\n* Planned surgery\\* if it might be within trial dates (\\* minor surgery not affecting adherence to treatment is allowed)",{"count":98,"type":21},40,[100],"NA","This prospective, open-labelled, longitudinal, controlled study aims to evaluate the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for adults with refractory chronic constipation who are awaiting trans-anal irrigation (TAI). The ICE treatment will be applied using the MOWOOT device (USMIMA). The study involves two treatment groups: an experimental group receiving daily ICE treatments and a control group following standard TAI care. Participants will serve as their own controls in pre- and post-treatment analyses to assess changes in bowel management satisfaction and other outcomes.",[28],[104,105,106,107],"constipation","transit problems","Trans-Anal Irrigation","Intermittent Colonic Exoperistalsis","2026-01-20",{"date":110,"type":38},"2026-01-22",{"date":112,"type":38},"2025-06-25",{"date":114,"type":21},"2026-09-01",{"name":116,"class":117},"usMIMA S.L.","INDUSTRY"]